Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DDR1/CD167a drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (ECD) | DDR1 ECD-Fc Fusion Protein HEK293 Expressed, Native Glycosylation, High Purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Ideal for collagen-binding assays. |
View DDR1 Products |
| Antigen (Kinase Domain) | DDR1 Kinase Domain (Active/Inactive) Theoretical MW verified, High Purity (>90%), for enzymatic inhibition assays. |
View DDR1 Products |
| Gene Delivery | DDR1 Full-Length ORF Lentivirus Native conformation for stable cell line construction. CMV promoter, Puro selection marker. |
View DDR1 Products |
| Benchmark Ab | Anti-DDR1 Neutralizing Antibody Sequence-verified recombinant rabbit monoclonal positive control for binding and blockade assays. |
View DDR1 Products |
| Validator | DDR1 siRNA Set Sequence-verified siRNA for knockdown verification and specificity controls. |
View DDR1 Products |
| Related Target: DDR2 | DDR2 ECD-Fc / Kinase Domain Essential for selectivity screening vs. highly homologous DDR family member. |
View DDR2 Products |
| Related Target: COL1A1 | Collagen Type I (Ligand) Native or recombinant ligand for binding competition assays. |
View COL1A1 Products |
| Related Target: TGFB1 | TGFB1 Synergistic fibrosis pathway partner; tumor microenvironment remodeling. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno DDR1 ortholog ECD proteins available with >95% purity, Sequence Verified. |
| DDR1 vs DDR2 subfamily selectivity | Homolog panel proteins (DDR1/DDR2 ECD) strictly verified by mass spec; Theoretical MW confirmed. |
| Collagen-binding Integrity (Discoidin Domain) | HEK293-expressed ECD preserves post-translational modifications critical for native collagen recognition. |
| Intracellular Target Screening (Small Molecules) | Recombinant Kinase Domains available; Sequence Verified, Theoretical MW. |
| Lack of Controls | Sequence-verified Anti-DDR1 recombinant benchmark antibody included for assay standardization. |
| False Positives | Sequence-verified DDR1 siRNA included for specificity checks and target engagement confirmation. |
Live DDR1/CD167a R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DDR1 (Discoidin Domain Receptor 1) therapeutics is intensifying, driven by its unique role as a collagen-activated receptor tyrosine kinase. As a critical mediator of tumor microenvironment (TME) rigidity and tissue fibrosis, major players are shifting focus from early generation pan-kinase inhibitors to highly selective small molecules and monoclonal antibodies. As first-generation therapies advance in idiopathic pulmonary fibrosis (IPF) and stroma-rich solid tumors, the next wave of R&D is targeting DDR1 degradation via PROTACs and sophisticated biologics capable of blocking the collagen-binding discoidin domain. The shift from oncology monotherapy to fibrosis indications and combination strategies is a key trend, with allosteric inhibitors and biologic modalities (mAbs/ADCs) emerging to distinguish pathological versus homeostatic collagen signaling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Global Pharma & Biotech Innovators (e.g., Principia, Repare, Nuvation Bio, Blueprint Medicines, Merck) | IPF, Solid Tumors (Pancreatic/Breast Cancer) | Cell-Based Kinase Assay (Need full-length DDR1 Lentivirus stable line) |
| Monoclonal Antibody | Oncology-Focused Biotechs, Preclinical Pipelines | Oncology, Fibrosis (Kidney Fibrosis, Atherosclerosis) | Collagen Competition Binding (Need high-purity DDR1 ECD-Fc) |
| Antibody-Drug Conjugate | Emerging Pipeline Developers, Preclinical Programs | DDR1-High Solid Tumors (Fibrotic Cancers) | Internalization Assay (Need high-purity ECD-Fc and stable cell lines) |
| PROTAC / Degrader | Academic / Emerging Bio | Chemo-refractory Tumors | Degradation Validation (Need Lentivirus for Cell Lines) |
| Allosteric Inhibitor | Early Discovery | Non-oncology indications | Conformational Binding Assay (Need stable ECD truncations) |